Ignite Creation Date:
2025-12-24 @ 7:54 PM
Ignite Modification Date:
2026-02-25 @ 5:11 PM
Study NCT ID:
NCT00596804
Status:
COMPLETED
Last Update Posted:
2021-08-18
First Post:
2008-01-08
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma
Sponsor:
Gilead Sciences
Organization:
Study Overview
Official Title:
A Phase I Study of Immunotherapy With hA20 Administered Once Weekly for 4 Consecutive Weeks in Patients With CD20+ Non- Hodgkin's Lymphoma
Status:
COMPLETED
Status Verified Date:
2012-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is being done to assess the safety and tolerance of different doses of humanized hA20 in patients with NHL.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: